Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Angiogenesis inhibitors are a novel class of promising therapeutic agents for treating cancer and other human diseases. Fumagillin and ovalicin compose a class of structurally related natural products that potently inhibit angiogenesis by blocking endothelial cell proliferation. A synthetic analog of fumagillin, TNP-470, is currently undergoing clinical trials for treatment of a variety of cancers. A common target for fumagillin and ovalicin recently was identified as the type 2 methionine aminopeptidase (MetAP2). These natural products bind MetAP2 covalently, inhibiting its enzymatic activity. The specificity of this binding is underscored by the lack of inhibition of the closely related type 1 enzyme, MetAP1. The molecular basis of the high affinity and specificity of these inhibitors for MetAP2 has remained undiscovered. To determine the structural elements of these inhibitors and MetAP2 that are involved in this interaction, we synthesized fumagillin analogs in which each of the potentially reactive epoxide groups was removed either individually or in combination. We found that the ring epoxide in fumagillin is involved in the covalent modification of MetAP2, whereas the side chain epoxide group is dispensable. By using a fumagillin analog tagged with fluorescein, His-231 in MetAP2 was identified as the residue that is covalently modified by fumagillin. Site-directed mutagenesis of His-231 demonstrated its importance for the catalytic activity of MetAP2 and confirmed that the same residue is covalently modified by fumagillin. These results, in agreement with a recent structural study, suggest that fumagillin and ovalicin inhibit MetAP2 by irreversible blockage of the active site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
Ingber, D., Fujita, T., Kishimoto, S., Sudo, K., Kanamaru, T., Brem, H., & Folkman, J. (1990) · Nature · doi:10.1038/348555a0 · Cited by 1,299
(1985) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60946-x · Cited by 1,071
TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION
Gimbrone, M. A., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.2.261 · Cited by 903
Direct Evidence for the Presence of Histidine in the Active Center of Chymotrypsin*
Schoellmann, G., & Shaw, E. (1963) · Biochemistry · doi:10.1021/bi00902a008 · Cited by 643
Sin, N., Meng, L., Wang, M. Q. W., Wen, J. J., Bornmann, W. G., & Crews, C. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6099 · Cited by 635
Ben-Bassat, A., Bauer, K., Chang, S. Y., Myambo, K., Boosman, A., & Chang, S. (1987) · Journal of Bacteriology · doi:10.1128/jb.169.2.751-757.1987 · Cited by 506
N-Terminal processing: the methionine aminopeptidase and Nα-acetyl transferase families
Bradshaw, R. A., Brickey, W. W., & Walker, K. W. (1998) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(98)01227-4 · Cited by 451
Cited by
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Differential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 741
Inhibition of angiogenesis decreases alveolarization in the developing rat lung
Jakkula, M., Le Cras, T. D., Gebb, S., Hirth, K. P., Tuder, R. M., Voelkel, N. F., & Abman, S. H. (2000) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2000.279.3.l600 · Cited by 680
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Angiogenesis Inhibitors: Current Strategies and Future Prospects
Cook, K. M., & Figg, W. D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20075 · Cited by 474
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
Oxidative Cyclization in Natural Product Biosynthesis
Tang, M.-C., Zou, Y., Watanabe, K., Walsh, C. T., & Tang, Y. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00478 · Cited by 425
Angiogenesis in the atherosclerotic plaque
Camaré, C., Pucelle, M., Nègre-Salvayre, A., & Salvayre, R. (2017) · Redox Biology · doi:10.1016/j.redox.2017.01.007 · Cited by 401
“Antiangiogenic molecules, endostatine and fumagillin [317] tested in ApoE mice induce a reduction of atherosclerotic lesions and macrophages infiltration [21].”
BackgroundMetalloaminopeptidases: Common Functional Themes in Disparate Structural Surroundings
Lowther, W. T., & Matthews, B. W. (2002) · Chemical Reviews · doi:10.1021/cr0101757 · Cited by 350
Protein N-terminal methionine excision
Giglione, C., Boularot, A., & Meinnel, T. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3466-8 · Cited by 336
Structure and function of the methionine aminopeptidases
Lowther, W. T., & Matthews, B. W. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00271-x · Cited by 317
Electrophilic natural products and their biological targets
Gersch, M., Kreuzer, J., & Sieber, S. A. (2012) · Natural Product Reports · doi:10.1039/c2np20012k · Cited by 282
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 270
Kallander, L. S., Lu, Q., Chen, W., Tomaszek, T., Yang, G., Tew, D., Meek, T. D., Hofmann, G. A., Schulz-Pritchard, C. K., Smith, W. W., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050408c · Cited by 189
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178
“Probably the best known historic example of serendipitous discovery of His-binding agent is natural product fumagillin that was shown to inhibit methionine aminopeptidase-2 (MetAP-2) by binding to His231 (Griffith et al., 1998) (Liu et al.”
BackgroundCell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1/CIP1
Zhang, Y., Griffith, E. C., Sage, J., Jacks, T., & Liu, J. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6427 · Cited by 175
Self-citationWinter, P. M., Caruthers, S. D., Zhang, H., Williams, T. A., Wickline, S. A., & Lanza, G. M. (2008) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2008.06.003 · Cited by 166
Aging-induced biological changes and cardiovascular diseases.
Fajemiroye, J. O., Cunha, L. C. D., Saavedra-Rodríguez, R., Rodrigues, K. L., Naves, L. M., Mourão, A. A., Silva, E. F. D., Williams, N. E. E., Martins, J. L. R., Sousa, R. B., et al. (2018) · BioMed Research International · doi:10.1155/2018/7156435 · Cited by 109
“Recent advances in cellular research have suggested new possibilities for the pharmacological treatment of atherosclerosis [118, 133].”
BackgroundMolina, J.-M., Goguel, J., Sarfati, C., Michiels, J.-F., Desportes-Livage, I., Balkan, S., Chastang, C., Cotte, L., Maslo, C., Struxiano, A., et al. (2000) · AIDS · doi:10.1097/00002030-200007070-00006 · Cited by 71
Houck, K. (2022) · ALTEX · doi:10.14573/altex.2203041 · Cited by 20
“The other major correlated profile was that of the fumagillin analog TNP-40, which inhibits angiogenesis through irreversible inactivation of methionine aminopeptidase-2 (MetAP2), blocking endothelial cell proliferation in vitro and angiogenesis in vivo (Griffith et al., 1998).”
Metadata
- Authors
- Griffith, E. C., Su, Z., Niwayama, S., Ramsay, C. A., Chang, Y.-H., & Liu, J. O.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-12-22
- Volume
- 95
- Issue
- 26
- Pages
- 15183-15188
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2072300064
- Cited by
- 262
- References
- 19
- FWCI
- 3.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.